Travere Therapeutics (TVTX) to Release Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) will likely be posting its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.14. The company had revenue of $94.84 million for the quarter, compared to the consensus estimate of $100.18 million. Travere Therapeutics had a negative return on equity of 717.68% and a negative net margin of 50.64%.The firm's revenue for the quarter was up 111.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.65) earnings per share. On average, analysts expect Travere Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Travere Therapeutics Price Performance

NASDAQ:TVTX opened at $27.48 on Thursday. The company has a current ratio of 2.00, a quick ratio of 1.98 and a debt-to-equity ratio of 9.50. The company has a market capitalization of $2.45 billion, a P/E ratio of -13.47 and a beta of 0.83. Travere Therapeutics has a 12 month low of $12.91 and a 12 month high of $28.69. The business's 50-day moving average is $22.83 and its 200 day moving average is $18.55.

Insider Buying and Selling at Travere Therapeutics

In other news, insider Elizabeth E. Reed sold 10,000 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the insider directly owned 89,878 shares in the company, valued at approximately $2,246,950. This represents a 10.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 10,573 shares of company stock valued at $260,608 in the last quarter. Corporate insiders own 4.19% of the company's stock.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TVTX. Raymond James Financial Inc. purchased a new stake in shares of Travere Therapeutics in the second quarter worth approximately $33,000. Headlands Technologies LLC purchased a new stake in shares of Travere Therapeutics in the second quarter worth approximately $73,000. Gallagher Fiduciary Advisors LLC purchased a new stake in shares of Travere Therapeutics in the second quarter worth approximately $155,000. Tower Research Capital LLC TRC raised its holdings in shares of Travere Therapeutics by 609.4% in the second quarter. Tower Research Capital LLC TRC now owns 24,998 shares of the company's stock worth $370,000 after buying an additional 21,474 shares during the period. Finally, Cresset Asset Management LLC raised its holdings in shares of Travere Therapeutics by 26.5% in the second quarter. Cresset Asset Management LLC now owns 28,875 shares of the company's stock worth $427,000 after buying an additional 6,047 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on TVTX shares. Scotiabank reiterated an "outperform" rating on shares of Travere Therapeutics in a research report on Thursday, August 7th. Citigroup reiterated a "buy" rating on shares of Travere Therapeutics in a research report on Sunday, August 10th. Wall Street Zen upgraded Travere Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, October 4th. HC Wainwright reissued a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a research note on Friday, September 19th. Finally, Stifel Nicolaus boosted their price objective on Travere Therapeutics from $20.00 to $25.00 and gave the stock a "hold" rating in a research note on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Travere Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $35.21.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.